Big data methods applied to the fitness landscape of the HIV envelope protein

February 7, 2018, Hong Kong University of Science and Technology
Computational method to estimate the fitness landscape of HIV-envelope. Credit: Department of Electronic & Computer Engineering, HKUST

Despite significant advances in medicine, there is still no effective vaccine for the human immunodeficiency virus (HIV), although recent hope has emerged through the discovery of antibodies capable of neutralizing diverse HIV strains. However, HIV can sometimes evade known broadly neutralizing antibody responses via mutational pathways, which makes it all the more difficult to design an effective solution.

An ideal vaccine would elicit broadly neutralizing antibodies that target parts of the virus's spike proteins where mutations severely compromise viral fitness or the ability to replicate. This requires knowledge of the fitness , a mapping from sequence to fitness. To achieve this goal, data scientists from the HKUST and their collaborators from MIT have employed a computational approach to estimate the fitness landscape of gp160, the polyprotein that comprises HIV's spike. The inferred landscape was then validated through comparisons with diverse experimental measurements.

Their findings were published in the journal PNAS in January 2018.

"Without big data machine learning methods, it is simply impossible to make such a prediction," said Raymond Louie, co-author, Junior Fellow of HKUST's Institute for Advanced Study and Research Assistant Professor in the Department of Electronic & Computer Engineering. "The number of parameters to be estimated came close to 4.4 million."

The data processed by the team consisted of 815 residues and 20,043 sequences from 1,918 HIV-infected individuals.

"The computational method gave us fast and accurate results," said Matthew McKay, co-author and Hari Harilela Associate Professor in the Departments of Electronic & Computer Engineering and Chemical & Biological Engineering at HKUST. "The findings can assist biologists in proposing new immunogens and vaccination protocols that seek to force the virus to mutate to unfit states in order to evade immune responses, which is likely to thwart or limit viral infection."

"While this method was developed to address the specific challenges posed by the gp160 protein, which we could not address using methods we developed to obtain the fitness landscapes of other HIV proteins, the approach is general and may be applied to other high-dimensional, maximum-entropy inference problems," said co-author Arup K. Chakraborty, the Robert T. Haslam Professor in Chemical Engineering, Physics, and Chemistry at MIT's Institute for Medical Engineering & Science. "Specifically, our fitness landscape could be clinically useful in the future for the selection of combination bnAb therapy and immunogen design."

"This is a multi-disciplinary study presenting an application of data science, and big data machine learning methods in particular, for addressing a challenging problem in biology," said McKay.

Explore further: Researchers chart 'fitness landscape' to fight Hep C virus

More information: Raymond H. Y. Louie et al, Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies, Proceedings of the National Academy of Sciences (2018). DOI: 10.1073/pnas.1717765115

Related Stories

Researchers chart 'fitness landscape' to fight Hep C virus

November 30, 2015
Borrowing from several statistical science models, an interdisciplinary team of researchers from the University of Illinois at Urbana-Champaign has developed a novel computational approach for massively accelerating the search ...

Study offers new way to discover HIV vaccine targets

March 21, 2013
Decades of research and three large-scale clinical trials have so far failed to yield an effective HIV vaccine, in large part because the virus evolves so rapidly that it can evade any vaccine-induced immune response.

Study establishes benchmarks for HIV vaccine candidates

December 27, 2017
The development of a vaccine that protects against HIV infections has proven extraordinarily difficult. One of the reasons is that naïve precursor B cells that can give rise to mature B cells producing broadly neutralizing ...

Antibodies show effectiveness for HIV prevention and promise for treatment and cure

January 17, 2018
The ability of HIV to mutate has been a major challenge to vaccine development. As the body produces antibodies to target the outer HIV envelope protein, this protein changes, thwarting the circulating antibodies' ability ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Researchers model alternate ideas for an HIV vaccine

September 18, 2015
Scientists at Los Alamos National Laboratory have created a computational model that could change the way that researchers look at possibilities for an HIV-1 vaccine.

Recommended for you

Proof-of-concept HIV immunotherapy study passes Phase 1 safety trial

September 21, 2018
Preliminary results from a phase I clinical trial have demonstrated the safety and tolerability of a cell therapy involving the ex vivo expansion of T cells and their subsequent infusion into HIV-infected individuals previously ...

FRESH program combines basic science with social benefits for women at risk of HIV

September 14, 2018
A program established by investigators from the Ragon Institute of Massachusetts General Hospital (MGH), MIT and Harvard is addressing the persistently elevated risk of HIV infection among young women in South Africa from ...

New study finds HIV outbreak in Indiana could have been prevented

September 13, 2018
An HIV outbreak among people who inject drugs in Indiana from 2011 to 2015 could have been avoided if the state's top health and elected officials had acted sooner on warnings, a new study by the Yale School of Public Health ...

Largest study of 'post-treatment controllers' reveals clues about HIV remission

September 13, 2018
Most HIV patients need to take daily anti-retroviral therapy—if they suspend treatment, HIV will rebound within 3-4 weeks. But clinical trials have revealed that a small fraction of patients can stop taking medications ...

Very few sexually active gay and bisexual men use prophylactic drug to prevent HIV transmission, study finds

September 12, 2018
Only 4 percent of sexually active gay and bisexual men in the United States use Truvada, a highly effective medication used to prevent the transmission of HIV, according to the results of a first-of-its-kind study.

Special antibodies could lead to HIV vaccine

September 10, 2018
Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against HIV. Researchers from the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.